Pharmaceutical major Cipla Limited on Wednesday declared its association with the Premier Medical Corporation Private Limited for commercialisation of the quick antigen test units to distinguish Coronavirus sickness (Covid-19) in India that will identify the viral illness in pretty much 15-20 minutes.
The organization will begin providing the units from this week, it said in an articulation.
This is Cipla’s second dispatch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit, which is a test unit to identify antibodies against the infection that causes Covid-19.
“In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited,” said the company in a statement issued on Wednesday.
The test is a quick purpose of-care nasopharyngeal swab test that straightforwardly identifies the presence or nonappearance of Covid antigen in the patient’s body, producing results inside 15-20 minutes. Just approved labs are allowed by ICMR to direct the quick antigen testing. The test will be advertised under the brand name ‘CIPtest’.
“CIPtest is a reliable high-performing kit that has been validated and approved by ICMR. It is found to have specificity and sensitivity of 98.09% and up to 75% respectively. It is not only rapid with a quick turn-around time, but also enables easy interpretation of results without the need of any additional instrument. Cipla’s expansive distribution network will help in ensuring supply of kits across the country,” the company statement added.
The medication major had likewise tied up with Hyderabad-based Council of Scientific and Industrial Research (CSIR)- Indian Institute of Chemical Technology (IICT) to chip away at hostile to viral medications against Covid-19.
Looking to repurpose certain all around accessible medication particles, the coordinated effort had been dealing with three atoms, remdesivir, favipiravir and baloxavir.
While remdesivir was initially evolved to treat the Ebola infection illness, favipiravir and baloxavir are hostile to virals affirmed for treating flu An and B.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Glean News journalist was involved in the writing and production of this article.